All In Biotech

Drug Trial Radar · NCT01848106

A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI

A Randomized, Open-Label, Multi-Center, Active-Controlled, Parallel Group Study To Determine the Efficacy and Safety of the REG1 Anticoagulation System Compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention

Last checked: Nov 20, 2026Latest source record: Oct 23, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 3,232 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

3,232

Actual

Start

Sep 2013

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Regado Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
The Cleveland Clinic; Duke Clinical Research Institute; Canadian VIGOUR Centre; Icahn School of Medicine at Mount Sinai; Parexel
First posted
May 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to determine the efficacy of REG1 compared to bivalirudin in preventing periprocedural ischemic complications and major bleeding in patients undergoing PCI as a treatment for CAD. Bivalirudin has been studied in patients undergoing PCI in both ACS (NSTEMI and unstable angina \[UA\]) and elective PCI. In comparison to UFH, bivalirudin has shown similar rates of ischemic events while demonstrating a significant reduction in bleeding and an improved net clinical benefit. Evidence from previous studies indicates that pegnivacogin represents an extremely potent, chemically unique anticoagulant that can be reversed by anivamersen across multiple populations (refer to Section 1.2.2). The question that still remains is whether Factor IX (FIX) inhibition by pegnivacogin can result in fewer ischemic events than a previously studied agent while active control with anivamersen can preserve the benefit of reduced bleeding. The purpose of this study is to evaluate REG1 in an adequately powered definitive study with an open-label, multi-center, active-controlled, randomized design to answer that question.

Conditions

  • Coronary Artery Disease

Interventions

  • pegnivacogin/anivamersenDrug

  • BivalirudinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ischemic compositeTime frame: Day 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Black Hills Cardiovascular Research

    Rapid City, South Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.